DrugPatentWatch Database Preview
Drugs in Development Information for D-Tryptophan
Drug Development Status for D-Tryptophan: Sponsors, patents, clinical trial progress
D-Tryptophan is an investigational drug.
There have been 13 clinical trials for D-Tryptophan.
The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2003.
The most common disease conditions in clinical trials are Breast Neoplasms, Adenocarcinoma, and Pancreatic Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), NewLink Genetics Corporation, and Southwest Oncology Group.
Summary for D-Tryptophan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,712 |
| WIPO Patent Applications | 1,277 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 1 (2003-08-01) |
| Vendors | 83 |
Recent Clinical Trials for D-Tryptophan
| Title | Sponsor | Phase |
|---|---|---|
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | National Cancer Institute (NCI) | Phase 3 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Southwest Oncology Group | Phase 3 |
| Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | University of Colorado, Denver | Phase 2 |
Clinical Trial Summary for D-Tryptophan
Top disease conditions for D-Tryptophan
Top clinical trial sponsors for D-Tryptophan
US Patents for D-Tryptophan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
